AU2001264564A1 - Composition and methods for treating photoreceptor degeneration - Google Patents

Composition and methods for treating photoreceptor degeneration

Info

Publication number
AU2001264564A1
AU2001264564A1 AU2001264564A AU6456401A AU2001264564A1 AU 2001264564 A1 AU2001264564 A1 AU 2001264564A1 AU 2001264564 A AU2001264564 A AU 2001264564A AU 6456401 A AU6456401 A AU 6456401A AU 2001264564 A1 AU2001264564 A1 AU 2001264564A1
Authority
AU
Australia
Prior art keywords
composition
methods
photoreceptor degeneration
treating photoreceptor
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264564A
Inventor
Judith M. Ogilvie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRAL INST DEAF
Original Assignee
CENTRAL INST DEAF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRAL INST DEAF filed Critical CENTRAL INST DEAF
Publication of AU2001264564A1 publication Critical patent/AU2001264564A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine
AU2001264564A 2000-05-02 2001-05-01 Composition and methods for treating photoreceptor degeneration Abandoned AU2001264564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20130200P 2000-05-02 2000-05-02
US60201302 2000-05-02
PCT/US2001/013992 WO2001083714A2 (en) 2000-05-02 2001-05-01 Composition and methods for treating photoreceptor degeneration

Publications (1)

Publication Number Publication Date
AU2001264564A1 true AU2001264564A1 (en) 2001-11-12

Family

ID=22745297

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264564A Abandoned AU2001264564A1 (en) 2000-05-02 2001-05-01 Composition and methods for treating photoreceptor degeneration

Country Status (2)

Country Link
AU (1) AU2001264564A1 (en)
WO (1) WO2001083714A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493849A1 (en) 2002-07-12 2004-01-22 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
KR20120137513A (en) 2007-04-20 2012-12-21 어큐셀라 인코포레이티드 Styrenyl derivative compounds for treating ophthalmic diseases and disorders
KR101196680B1 (en) 2007-06-29 2012-11-06 어큐셀라 인코포레이티드 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
NZ584599A (en) 2007-10-05 2012-07-27 Acucela Inc Alkoxy compounds for disease treatment
US9447078B2 (en) 2012-01-20 2016-09-20 Acucela Inc. Substituted heterocyclic compounds for disease treatment
EA201591535A1 (en) 2013-03-12 2016-04-29 Акусела Инк. SUBSTITUTED DERIVATIVES OF 3-PHENYL-PROPYLAMINE FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND DISORDERS
WO2016094876A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624957A (en) * 1984-06-20 1986-11-25 Schachar Ronald A Treatment and prevention of retinal edema with dopaminergic antagonists
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
US5252568A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine
WO2001030337A2 (en) * 1999-10-22 2001-05-03 Orbon Corporation Ophthalmic formulation of dopamine antagonists

Also Published As

Publication number Publication date
WO2001083714A2 (en) 2001-11-08
WO2001083714A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2002219945A1 (en) Composition and method for treating snoring
AU2001288249A1 (en) Biosensors and methods for their use
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
IL144517A0 (en) Compositions and methods for treating cataracts
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
AU2001279850A1 (en) Method and arrangement for studsystem
AU4100199A (en) Compositions and methods for enhancing protein anabolism and detoxification
AUPR152100A0 (en) Method for treating coral
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2001233932A1 (en) Method and composition
AU2001264564A1 (en) Composition and methods for treating photoreceptor degeneration
AU2001288736A1 (en) Method and composition for enhancing vision
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU2001278951A1 (en) Compounds and methods
AU2001261513A1 (en) Composition and method for increasing testosterone levels
AU2002239775A1 (en) Chemical-library composition and method
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU2002305700A1 (en) Composition and method for treating cells
AU2002256556A1 (en) Sea-trosy and related methods
AU7604100A (en) Composition and method for treating burns
AU5243899A (en) Methods and compositions for using moclobemide